Rocbrutinib is an orally available, highly selective Brutons tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkins lymphoma and mantle cell lymphoma[1][2].
Molekulargewicht:
761.91
Reinheit:
99.76
CAS Nummer:
[2485861-07-0]
Formel:
C42H51N9O5
Target-Kategorie:
EGFR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
